Run any Skill in Manus with one click

enda-avoid-long-acting-glucocorticoids-children

Stars5

Forks1

UpdatedJune 27, 2026 at 01:34

Suggests avoiding synthetic, long-acting glucocorticoids (e.g., prednisolone, dexamethasone) in children with primary adrenal insufficiency (PAI). Use when selecting glucocorticoid replacement for a child with PAI to prevent Cushingoid side effects and dose titration difficulties.

Installation

Install with Codex or Claude Copy this prompt, paste it into Codex, Claude, or another assistant, and let it review the skill page and install it for you.

Run Skill in Manus

Source

dromlakhani

dromlakhani/MD2SKILL

View GitHub Repository View Creator Repositories

Download

Run Skill in Manus

Related occupationsSOC

Based on SOC occupation classification

Pediatricians, GeneralHealthcare Practitioners and Technical Occupations·SOC 29-1221

SKILL.md

readonly

name	enda-avoid-long-acting-glucocorticoids-children
description	Suggests avoiding synthetic, long-acting glucocorticoids (e.g., prednisolone, dexamethasone) in children with primary adrenal insufficiency (PAI). Use when selecting glucocorticoid replacement for a child with PAI to prevent Cushingoid side effects and dose titration difficulties.

Avoid Synthetic, Long-Acting Glucocorticoids in Children with PAI

STEP 1 — Gather Information

Confirm diagnosis of PAI in the child (via ACTH stimulation test or clinical/lab criteria) and assess need for glucocorticoid replacement therapy.

STEP 2 — Rule In / Rule Out

If the child has PAI and requires glucocorticoid replacement, rule out synthetic, long-acting glucocorticoids (prednisolone, dexamethasone) due to risks in pediatric PAI.

STEP 3 — Classify or Stratify

Classify glucocorticoid options: preferred short-acting agents (hydrocortisone, cortisone acetate) versus avoided long-acting agents (prednisolone, dexamethasone).

STEP 4 — Decide

Initiate glucocorticoid replacement with hydrocortisone (8 mg/m²/day in three or four divided doses) or cortisone acetate (20–35 mg/day in two or three divided doses); avoid prednisolone and dexamethasone entirely.

Clinical Guardrails / Mimics / Pitfalls

Do not use dexamethasone due to high risk of Cushingoid side effects and difficulty in dose titration. Avoid prednisolone in children with PAI as it is long-acting and may cause overexposure; if hydrocortisone is unavailable, prednisolone is a last-resort alternative only with extreme caution (per guideline 3.3), but dexamethasone remains least preferred.

Concrete Clinical Example

A 6-year-old girl with PAI (autoimmune etiology) is started on hydrocortisone 9 mg/m²/day in three divided doses (5 mg/m² morning, 2 mg/m² noon, 2 mg/m² evening) after confirming low cortisol and high ACTH. Prednisolone and dexamethasone are avoided per guideline 3.19.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI: 10.1210/jc.2015-1710

More from this repository

same repository

genryzon-drug-interactions

dromlakhani/MD2SKILL

Drug-interaction and co-medication adjustment reference for a child on Genryzon (somatrogon, weekly long-acting growth hormone). Covers glucocorticoids, insulin and oral hypoglycaemics, thyroxine, oral estrogen, and CYP3A4-metabolised drugs (sex steroids, corticosteroids, anticonvulsants, ciclosporin). Use when a clinician asks about drug interactions with Genryzon or somatrogon, prescribing another drug in a child on GH, girl on Genryzon starting OCP, diabetic child starting GH, adjusting hydrocortisone on GH, or CYP3A4 concerns with somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-igf1-titration

dromlakhani/MD2SKILL

Titrate Genryzon (somatrogon, weekly long-acting growth hormone) dose in a paediatric GHD patient using serum IGF-1 SDS. Encodes the mandatory 4-days-post-dose sampling rule, the target SDS window, the 15% dose-reduction trigger, and the oral estrogen adjustment. Use when a clinician asks how to titrate somatrogon, when to sample IGF-1 on Genryzon, target IGF-1 SDS on weekly GH, what to do if IGF-1 is too high on somatrogon, IGF-1 rising on Genryzon, how to adjust GH dose in a girl started on oral OCP, or presents a paediatric GHD case on somatrogon with an IGF-1 value to interpret. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-prescribing-guide

dromlakhani/MD2SKILL

Bedside prescribing reference for Genryzon (somatrogon, Pfizer India) — the once-weekly long-acting growth hormone for paediatric growth hormone deficiency. Use when a clinician asks how to start Genryzon, how to dose somatrogon in a child, how to switch a child from daily growth hormone to weekly somatrogon, how to inject the Genryzon pen, missed-dose rule for somatrogon, when to stop somatrogon, or needs a monograph-level prescribing decision for a paediatric GHD patient. Applies to children and adolescents ≥3 years of age. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-pretreatment-screening

dromlakhani/MD2SKILL

Pretreatment screening checklist before starting Genryzon (somatrogon, weekly long-acting growth hormone) in a child with confirmed paediatric growth hormone deficiency. Ensures thyroid, adrenal, glucose, ocular, tumour, and Prader-Willi status are checked before the first dose to prevent adrenal crisis, wasted therapy, unmasked hypothyroidism, unrecognised hyperglycaemia, missed intracranial hypertension, or sudden death in PWS. Use when a clinician asks what to check before starting somatrogon, workup before Genryzon, baseline tests for weekly GH, screening for adrenal insufficiency before GH, or is about to prescribe Genryzon in a paediatric GHD case. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-red-flag-monitoring

dromlakhani/MD2SKILL

Red-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician asks what side effects to watch for on Genryzon, red flags on weekly GH, headache in a child on somatrogon, limp in a child on GH, abdominal pain on Genryzon, or is following up a paediatric GHD patient on somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-treatment-discontinuation

dromlakhani/MD2SKILL

Decide when to stop Genryzon (somatrogon, weekly long-acting growth hormone) in a paediatric GHD patient — the three physiological gates (epiphyseal closure, height velocity <2 cm/year, bone age >14 in girls or >16 in boys) plus the safety-driven stops (active tumour, adult GHD re-evaluation, adverse events). Use when a clinician asks when to stop somatrogon, when to discontinue Genryzon, is the child done with GH, has this child reached final height on GH, transitioning GH from paediatric to adult care, or is reviewing a teenager who has been on Genryzon for years. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

name	enda-avoid-long-acting-glucocorticoids-children
description	Suggests avoiding synthetic, long-acting glucocorticoids (e.g., prednisolone, dexamethasone) in children with primary adrenal insufficiency (PAI). Use when selecting glucocorticoid replacement for a child with PAI to prevent Cushingoid side effects and dose titration difficulties.

Avoid Synthetic, Long-Acting Glucocorticoids in Children with PAI

STEP 1 — Gather Information

Confirm diagnosis of PAI in the child (via ACTH stimulation test or clinical/lab criteria) and assess need for glucocorticoid replacement therapy.

STEP 2 — Rule In / Rule Out

If the child has PAI and requires glucocorticoid replacement, rule out synthetic, long-acting glucocorticoids (prednisolone, dexamethasone) due to risks in pediatric PAI.

STEP 3 — Classify or Stratify

Classify glucocorticoid options: preferred short-acting agents (hydrocortisone, cortisone acetate) versus avoided long-acting agents (prednisolone, dexamethasone).

STEP 4 — Decide

Clinical Guardrails / Mimics / Pitfalls

Concrete Clinical Example

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI: 10.1210/jc.2015-1710